Stratify Genomics was founded by a leading urologist who became concerned about the controversy surrounding PSA screening leading to delayed diagnosis and an increase in incurable disease in patients. Stratify is focused on solutions designed to curb this disturbing trend.
Stratify is dedicated to advancing the knowledge of genetic predisposition to cancer and other diseases so practitioners can screen more effectively and efficiently.
Prompt Prostate Genetic Score (PGS) is a major advancement in defining risk for prostate cancer. It is an easy to use polygenic risk score (PRS) test obtained from a buccal swab that analyzes over 30 Single Nucleotide Polymorphisms (SNPs) that reports a lifetime risk of developing prostate cancer and can help identify those high-risk men who may benefit most from prostate cancer screening and possibly even stratiegies to prevent prostate cancer. Prompt PGS provides actionable results across the entire spectrum of test results helping HCPs develop personalized prostate cancer screening protocols as well as providing important information for biopsy desicion making.
Visit Booth # 2535J
www.PromptPGS.com
Brands: Prompt Prostate Genetic Score (PGS) is a germline polygenic risk score (PRS) test that reports lifetime risk of developing prostate cancer.
Booth #2535J
www.PromptPGS.com
Supported by Stratify Genomics